Autophagy Inhibition Delays Early but Not Late-Stage Metastatic Disease.
Identifieur interne : 000205 ( PubMed/Curation ); précédent : 000204; suivant : 000206Autophagy Inhibition Delays Early but Not Late-Stage Metastatic Disease.
Auteurs : Rebecca A. Barnard ; Daniel P. Regan ; Ryan J. Hansen ; Paola Maycotte ; Andrew Thorburn ; Daniel L. Gustafson [États-Unis]Source :
- The Journal of pharmacology and experimental therapeutics [ 1521-0103 ] ; 2016.
Descripteurs français
- KwdFr :
- Animaux, Antinéoplasiques (pharmacologie), Apoptose (), Autophagie (), Chloroquine (pharmacologie), Cisplatine (pharmacologie), Facteurs temps, Femelle, Lignée cellulaire tumorale, Métastase tumorale, Prolifération cellulaire (), Souris, Stade de la tumeur, Synergie des médicaments, Traitement néoadjuvant, Tréhalose (pharmacologie).
- MESH :
English descriptors
- KwdEn :
- Animals, Antineoplastic Agents (pharmacology), Apoptosis (drug effects), Autophagy (drug effects), Cell Line, Tumor, Cell Proliferation (drug effects), Chloroquine (pharmacology), Cisplatin (pharmacology), Drug Synergism, Female, Mice, Neoadjuvant Therapy, Neoplasm Metastasis, Neoplasm Staging, Time Factors, Trehalose (pharmacology).
- MESH :
- chemical , pharmacology : Antineoplastic Agents, Chloroquine, Cisplatin, Trehalose.
- drug effects : Apoptosis, Autophagy, Cell Proliferation.
- Animals, Cell Line, Tumor, Drug Synergism, Female, Mice, Neoadjuvant Therapy, Neoplasm Metastasis, Neoplasm Staging, Time Factors.
Abstract
The autophagy pathway has been recognized as a mechanism of survival and therapy resistance in cancer, yet the extent of autophagy's function in metastatic progression is still unclear. Therefore, we used murine models of metastatic cancer to investigate the effect of autophagy modulation on metastasis development. Pharmacologic and genetic autophagy inhibition were able to impede cell proliferation in culture, but did not impact the development of experimentally induced 4T1 and B16-F10 metastases. Similarly, autophagy inhibition by adjuvant chloroquine (CQ) treatment did not delay metastasis in an orthotopic 4T1, tumor-resection model. However, neoadjuvant CQ treatment or genetic autophagy inhibition resulted in delayed metastasis development, whereas stimulation of autophagy by trehalose hastened development. Cisplatin was also administered either as a single agent or in combination with CQ. The combination of cisplatin and CQ was antagonistic. The effects of autophagy modulation on metastasis did not appear to be due to alterations in the intrinsic metastatic capability of the cells, as modulating autophagy had no impact on migration, invasion, or anchorage-independent growth in vitro. To explore the possibility of autophagy's influence on the metastatic microenvironment, bone marrow-derived cells (BMDCs), which mediate the establishment of the premetastatic niche, were measured in the lung and in circulation. Trehalose-treated mice had significantly more BMDCs than either vehicle- or CQ-treated mice. Autophagy inhibition may be most useful as a treatment to impede early metastatic development. However, modulating autophagy may also alter the efficacy of platinum-based therapies, requiring caution when considering combination therapies.
DOI: 10.1124/jpet.116.233908
PubMed: 27231155
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000205
Links to Exploration step
pubmed:27231155Curation
No country items
Rebecca A. Barnard<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Autophagy Inhibition Delays Early but Not Late-Stage Metastatic Disease.</title>
<author><name sortKey="Barnard, Rebecca A" sort="Barnard, Rebecca A" uniqKey="Barnard R" first="Rebecca A" last="Barnard">Rebecca A. Barnard</name>
<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Regan, Daniel P" sort="Regan, Daniel P" uniqKey="Regan D" first="Daniel P" last="Regan">Daniel P. Regan</name>
<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Hansen, Ryan J" sort="Hansen, Ryan J" uniqKey="Hansen R" first="Ryan J" last="Hansen">Ryan J. Hansen</name>
<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Maycotte, Paola" sort="Maycotte, Paola" uniqKey="Maycotte P" first="Paola" last="Maycotte">Paola Maycotte</name>
<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Thorburn, Andrew" sort="Thorburn, Andrew" uniqKey="Thorburn A" first="Andrew" last="Thorburn">Andrew Thorburn</name>
<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Gustafson, Daniel L" sort="Gustafson, Daniel L" uniqKey="Gustafson D" first="Daniel L" last="Gustafson">Daniel L. Gustafson</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.) Daniel.Gustafson@colostate.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27231155</idno>
<idno type="pmid">27231155</idno>
<idno type="doi">10.1124/jpet.116.233908</idno>
<idno type="wicri:Area/PubMed/Corpus">000205</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000205</idno>
<idno type="wicri:Area/PubMed/Curation">000205</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000205</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Autophagy Inhibition Delays Early but Not Late-Stage Metastatic Disease.</title>
<author><name sortKey="Barnard, Rebecca A" sort="Barnard, Rebecca A" uniqKey="Barnard R" first="Rebecca A" last="Barnard">Rebecca A. Barnard</name>
<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Regan, Daniel P" sort="Regan, Daniel P" uniqKey="Regan D" first="Daniel P" last="Regan">Daniel P. Regan</name>
<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Hansen, Ryan J" sort="Hansen, Ryan J" uniqKey="Hansen R" first="Ryan J" last="Hansen">Ryan J. Hansen</name>
<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Maycotte, Paola" sort="Maycotte, Paola" uniqKey="Maycotte P" first="Paola" last="Maycotte">Paola Maycotte</name>
<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Thorburn, Andrew" sort="Thorburn, Andrew" uniqKey="Thorburn A" first="Andrew" last="Thorburn">Andrew Thorburn</name>
<affiliation><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</nlm:affiliation>
<wicri:noCountry code="subField">A.T.).</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Gustafson, Daniel L" sort="Gustafson, Daniel L" uniqKey="Gustafson D" first="Daniel L" last="Gustafson">Daniel L. Gustafson</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.) Daniel.Gustafson@colostate.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of pharmacology and experimental therapeutics</title>
<idno type="eISSN">1521-0103</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antineoplastic Agents (pharmacology)</term>
<term>Apoptosis (drug effects)</term>
<term>Autophagy (drug effects)</term>
<term>Cell Line, Tumor</term>
<term>Cell Proliferation (drug effects)</term>
<term>Chloroquine (pharmacology)</term>
<term>Cisplatin (pharmacology)</term>
<term>Drug Synergism</term>
<term>Female</term>
<term>Mice</term>
<term>Neoadjuvant Therapy</term>
<term>Neoplasm Metastasis</term>
<term>Neoplasm Staging</term>
<term>Time Factors</term>
<term>Trehalose (pharmacology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antinéoplasiques (pharmacologie)</term>
<term>Apoptose ()</term>
<term>Autophagie ()</term>
<term>Chloroquine (pharmacologie)</term>
<term>Cisplatine (pharmacologie)</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Lignée cellulaire tumorale</term>
<term>Métastase tumorale</term>
<term>Prolifération cellulaire ()</term>
<term>Souris</term>
<term>Stade de la tumeur</term>
<term>Synergie des médicaments</term>
<term>Traitement néoadjuvant</term>
<term>Tréhalose (pharmacologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Chloroquine</term>
<term>Cisplatin</term>
<term>Trehalose</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term>
<term>Autophagy</term>
<term>Cell Proliferation</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Chloroquine</term>
<term>Cisplatine</term>
<term>Tréhalose</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line, Tumor</term>
<term>Drug Synergism</term>
<term>Female</term>
<term>Mice</term>
<term>Neoadjuvant Therapy</term>
<term>Neoplasm Metastasis</term>
<term>Neoplasm Staging</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Apoptose</term>
<term>Autophagie</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Lignée cellulaire tumorale</term>
<term>Métastase tumorale</term>
<term>Prolifération cellulaire</term>
<term>Souris</term>
<term>Stade de la tumeur</term>
<term>Synergie des médicaments</term>
<term>Traitement néoadjuvant</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The autophagy pathway has been recognized as a mechanism of survival and therapy resistance in cancer, yet the extent of autophagy's function in metastatic progression is still unclear. Therefore, we used murine models of metastatic cancer to investigate the effect of autophagy modulation on metastasis development. Pharmacologic and genetic autophagy inhibition were able to impede cell proliferation in culture, but did not impact the development of experimentally induced 4T1 and B16-F10 metastases. Similarly, autophagy inhibition by adjuvant chloroquine (CQ) treatment did not delay metastasis in an orthotopic 4T1, tumor-resection model. However, neoadjuvant CQ treatment or genetic autophagy inhibition resulted in delayed metastasis development, whereas stimulation of autophagy by trehalose hastened development. Cisplatin was also administered either as a single agent or in combination with CQ. The combination of cisplatin and CQ was antagonistic. The effects of autophagy modulation on metastasis did not appear to be due to alterations in the intrinsic metastatic capability of the cells, as modulating autophagy had no impact on migration, invasion, or anchorage-independent growth in vitro. To explore the possibility of autophagy's influence on the metastatic microenvironment, bone marrow-derived cells (BMDCs), which mediate the establishment of the premetastatic niche, were measured in the lung and in circulation. Trehalose-treated mice had significantly more BMDCs than either vehicle- or CQ-treated mice. Autophagy inhibition may be most useful as a treatment to impede early metastatic development. However, modulating autophagy may also alter the efficacy of platinum-based therapies, requiring caution when considering combination therapies.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27231155</PMID>
<DateCompleted><Year>2017</Year>
<Month>05</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-0103</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>358</Volume>
<Issue>2</Issue>
<PubDate><Year>2016</Year>
<Month>08</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of pharmacology and experimental therapeutics</Title>
<ISOAbbreviation>J. Pharmacol. Exp. Ther.</ISOAbbreviation>
</Journal>
<ArticleTitle>Autophagy Inhibition Delays Early but Not Late-Stage Metastatic Disease.</ArticleTitle>
<Pagination><MedlinePgn>282-93</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.116.233908</ELocationID>
<Abstract><AbstractText>The autophagy pathway has been recognized as a mechanism of survival and therapy resistance in cancer, yet the extent of autophagy's function in metastatic progression is still unclear. Therefore, we used murine models of metastatic cancer to investigate the effect of autophagy modulation on metastasis development. Pharmacologic and genetic autophagy inhibition were able to impede cell proliferation in culture, but did not impact the development of experimentally induced 4T1 and B16-F10 metastases. Similarly, autophagy inhibition by adjuvant chloroquine (CQ) treatment did not delay metastasis in an orthotopic 4T1, tumor-resection model. However, neoadjuvant CQ treatment or genetic autophagy inhibition resulted in delayed metastasis development, whereas stimulation of autophagy by trehalose hastened development. Cisplatin was also administered either as a single agent or in combination with CQ. The combination of cisplatin and CQ was antagonistic. The effects of autophagy modulation on metastasis did not appear to be due to alterations in the intrinsic metastatic capability of the cells, as modulating autophagy had no impact on migration, invasion, or anchorage-independent growth in vitro. To explore the possibility of autophagy's influence on the metastatic microenvironment, bone marrow-derived cells (BMDCs), which mediate the establishment of the premetastatic niche, were measured in the lung and in circulation. Trehalose-treated mice had significantly more BMDCs than either vehicle- or CQ-treated mice. Autophagy inhibition may be most useful as a treatment to impede early metastatic development. However, modulating autophagy may also alter the efficacy of platinum-based therapies, requiring caution when considering combination therapies.</AbstractText>
<CopyrightInformation>Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barnard</LastName>
<ForeName>Rebecca A</ForeName>
<Initials>RA</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Regan</LastName>
<ForeName>Daniel P</ForeName>
<Initials>DP</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hansen</LastName>
<ForeName>Ryan J</ForeName>
<Initials>RJ</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Maycotte</LastName>
<ForeName>Paola</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thorburn</LastName>
<ForeName>Andrew</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gustafson</LastName>
<ForeName>Daniel L</ForeName>
<Initials>DL</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado (R.A.B., D.P.R., R.J.H., D.L.G.); and Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado (P.M., A.T.) Daniel.Gustafson@colostate.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 CA046934</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 CA150925</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 CA190170</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 OD010437</GrantID>
<Acronym>OD</Acronym>
<Agency>NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>05</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Pharmacol Exp Ther</MedlineTA>
<NlmUniqueID>0376362</NlmUniqueID>
<ISSNLinking>0022-3565</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>B8WCK70T7I</RegistryNumber>
<NameOfSubstance UI="D014199">Trehalose</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>Q20Q21Q62J</RegistryNumber>
<NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014199" MajorTopicYN="N">Trehalose</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>03</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>05</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>5</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>5</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>5</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27231155</ArticleId>
<ArticleId IdType="pii">jpet.116.233908</ArticleId>
<ArticleId IdType="doi">10.1124/jpet.116.233908</ArticleId>
<ArticleId IdType="pmc">PMC4959099</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Cancer Discov. 2014 Apr;4(4):466-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24513958</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharmacol Exp Ther. 2013 Mar;344(3):544-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23291713</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Cell Physiol. 2013 Apr 1;304(7):C617-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23269239</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2010 Feb 5;140(3):313-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20144757</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Aug;10 (8):1369-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991839</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2011 Feb;7(2):188-204</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21107021</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2013 Dec;9(12 ):2056-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24157892</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Cell Biol. 2010 Apr;22(2):241-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19945838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2005 Dec 8;438(7069):820-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16341007</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Aug;10(8):1415-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991836</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell Biol. 2011 Sep;31(17 ):3616-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21709020</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Aug;10(8):1403-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991835</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2011 Feb 15;17(4):654-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21325294</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Exp Anim. 2011;60(4):329-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21791873</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2012 Jan 15;18(2):370-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22080440</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Death Differ. 2014 Jan;21(1):92-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24037090</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Treat Rep. 1987 Mar;71(3):297-304</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3815395</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Physiol. 2012 Jul 15;590(14):3305-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22570377</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharmacol Toxicol Methods. 2005 Nov-Dec;52(3):366-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16112590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chemotherapy. 2011;57(6):468-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22248721</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Aug;10(8):1380-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anticancer Drugs. 2013 Nov;24(10):1007-19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23962902</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2006 Jul;10 (1):51-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16843265</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2001 May 1;29(9):e45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11328886</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Mar;10(3):391-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24419177</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2014 May 1;74(9):2579-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24590058</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1991 Sep 15;266(26):17707-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1832676</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Cycle. 2013 Oct 15;12 (20):3317-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24036548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Treat Rep. 1983 Mar;67(3):235-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6682012</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 1992 Mar 15;52(6):1399-405</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1540948</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Lett. 2012 Jan 28;314(2):232-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22019047</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Biol Cell. 2008 Mar;19(3):797-806</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18094039</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2007 Nov-Dec;3(6):542-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17611390</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2011 Dec 16;334(6062):1573-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22174255</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013;8(3):e58207</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23472159</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 1975 Jan;35(1):218-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1109790</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2012 Feb 1;8(2):200-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22252008</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Cycle. 2012 May 15;11(10 ):2022-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22580450</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2009 Aug 4;16(2):91-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19647220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2012 Jul 1;8(7):1032-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22562073</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Chemother Pharmacol. 1987;20(1):26-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3621450</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anticancer Res. 1993 Sep-Oct;13(5A):1481-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8239525</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Aug;10 (8):1359-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991840</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2013 Jul;123(7):2907-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23921130</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Aug;10(8):1391-402</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Treat Options Oncol. 2005 May;6(3):185-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15869730</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2012 May 22;109 (21):8253-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22566612</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Cancer Biol. 2011 Apr;21(2):139-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21251983</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cancer Res. 2015 Apr;13(4):651-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25573951</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 1987 Dec 1;47(23):6297-301</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3315183</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Cancer. 1998 May 4;76(3):418-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9579581</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000205 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000205 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:27231155 |texte= Autophagy Inhibition Delays Early but Not Late-Stage Metastatic Disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:27231155" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |